Cargando…

Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy

Tumor recurrence is often attributed to cancer stem cells (CSCs). We previously demonstrated that down-regulation of Pregnane X Receptor (PXR) decreases the chemoresistance of CSCs and prevents colorectal cancer recurrence. Currently, no PXR inhibitor is usable in clinic. Here, we identify miR-148a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansard, Lucile, Bouvet, Océane, Moutin, Elisa, Le Gall, Gaétan, Giammona, Alessandro, Pothin, Elodie, Bacou, Marion, Hassen-Khodja, Cédric, Bordignon, Benoit, Bourgaux, Jean François, Prudhomme, Michel, Hollande, Frédéric, Pannequin, Julie, Pascussi, Jean Marc, Planque, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023769/
https://www.ncbi.nlm.nih.gov/pubmed/35276090
http://dx.doi.org/10.1016/j.stemcr.2022.02.005
Descripción
Sumario:Tumor recurrence is often attributed to cancer stem cells (CSCs). We previously demonstrated that down-regulation of Pregnane X Receptor (PXR) decreases the chemoresistance of CSCs and prevents colorectal cancer recurrence. Currently, no PXR inhibitor is usable in clinic. Here, we identify miR-148a as a targetable element upstream of PXR signaling in CSCs, which when over-expressed decreases PXR expression and impairs tumor relapse after chemotherapy in mouse tumor xenografts. We then develop a fluorescent reporter screen for miR-148a activators and identify the anti-helminthic drug niclosamide as an inducer of miR-148a expression. Consequently, niclosamide decreased PXR expression and CSC numbers in colorectal cancer patient-derived cell lines and synergized with chemotherapeutic agents to prevent CSC chemoresistance and tumor recurrence in vivo. Our study suggests that endogenous miRNA inducers is a viable strategy to down-regulate PXR and illuminates niclosamide as a neoadjuvant repurposing strategy to prevent tumor relapse in colon cancer.